Pharmaceutical Executive
As the fanfare over the sequencing of the human genome fades, the spotlight turns to the "shovel and pans" companies offering the tools investors are betting on to make "gene to drug" a reality.
As the fanfare over the sequencing of the human genome fades, the spotlight turns to the "shovel and pans" companies offering the tools investors are betting on to make "gene to drug" a reality.
Several in that industry, including Genzyme, Pyrosequencing, and Global Genomics mingled with investors from Merrill Lynch, Oxford BioScience Partners, and HealthCap at the Consul General of Sweden in New York. Hosted by Consul General Olle WÄstberg, executives discussed industry trends, the US Senate's division over human cloning, and the dwindling reliance on Big Pharma as the financier of biotech products and technologies.
In her keynote address, Mara Aspinall, president of Genzyme General, which specializes in treatments for genetic disorders, noted that definite challenges lie ahead in preparing systems for applied genomics. Those include obtaining the maximum amount of genetic information from patients to improve their health, protecting their genetic privacy, and providing genetics education for physicians, patients, and managed care decision makers.
Despite the obstacles, gene targeting will guide product development because it produces cost-effective therapeutics and there is a lower incidence of adverse drug reactions associated with it, according to Erik Wallden, CEO, Pyrosequencing.
Douglas Fambrough, PhD, an analyst from Oxford Bioscience Partners, predicted that small biotech and technology companies will be more likely to look to Big Biotech rather than Big Pharma for potential partners. He points to pharma's "technology indigestion" from 2000, when it grabbed up more technologies than it could process, and the long-awaited consolidation in the biotech field that enables biotech-biotech collaborations.
However, Magnus Persson, HealthCap partner, says "the backbone of those strategies is to work along the value chain toward pharma-where the real value lies."
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.